47,564 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 47,564 shares of the medical device company's stock, valued at approximately $3,699,000.

Several other large investors have also bought and sold shares of the company. Forvis Mazars Wealth Advisors LLC raised its holdings in DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after buying an additional 118 shares during the last quarter. Principal Securities Inc. lifted its holdings in shares of DexCom by 3.4% during the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after purchasing an additional 135 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Nia Impact Advisors LLC lifted its holdings in shares of DexCom by 1.4% during the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after purchasing an additional 140 shares in the last quarter. Finally, Level Four Advisory Services LLC lifted its holdings in shares of DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This trade represents a 10.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This represents a 4.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 66,926 shares of company stock valued at $4,734,384. Insiders own 0.32% of the company's stock.

DexCom Trading Down 1.7%

Shares of NASDAQ:DXCM traded down $1.49 during trading on Wednesday, hitting $85.85. The company had a trading volume of 622,201 shares, compared to its average volume of 4,344,496. The stock has a market cap of $33.66 billion, a price-to-earnings ratio of 59.96, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a one year low of $57.52 and a one year high of $131.76. The company has a fifty day simple moving average of $72.71 and a two-hundred day simple moving average of $77.87. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the business posted $0.32 earnings per share. DexCom's revenue was up 12.5% on a year-over-year basis. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on DXCM. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and increased their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Piper Sandler reduced their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Mizuho started coverage on DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.